Bina, SAS and others pitch new tools to boost biopharma R&D

Over the past week a host of tech providers have pitched new tools to improve biopharma R&D, with Ayasdi, Bina Technologies, SAS and others unveiling products and upgrades at Bio-IT World Expo.

Ayasdi and Genalice both talked up the gains achieved by optimizing their software to Intel's Xeon processors. Menlo Park, CA-based Ayasdi claims such optimization work improved the performance of its drug discovery platform, Ayasdi Cure, by 400%. CLC bio is integrating the tool into its bioinformatics platform. Dutch company Genalice is also working with Intel ($INTC). By tailoring its software to a simple dual Intel Xeon E5 server, Genalice mapped 42 complete human and 42 full tomato genomes in 24 hours.

Bina Technologies also trumpeted the time savings of its new approach. Using the Bina Annotation Platform, researchers can reportedly comprehensively annotate large NGS datasets in under one hour. Seven Bridges Genomics is trying to carve out a piece of the NGS data handling market too. The firm has partnered with BioTeam to make its repository of NGS tools available to researchers who are unable to access cloud-based systems.

SAS subsidiary JMP has updated its clinical and genomics software. Version 5.0 of the clinical package features new capabilities for risk-based monitoring of research. The genomics update is designed to improve the linking of clinical phenotypes to genetic variants and the discovery of biomarker profiles. Metabolon also moved to strengthen its biomarker discovery offering by debuting MetaboLync, a platform that allows its clients to share, visualize and explore metabolomics study results.

- read the Ayasdi release
- here's Genalice's news
- check out Bina's item
- view Seven Bridges' post
- read SAS' release
- and Metabolon's news